Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data
Anderson, George M.
Arnold, L. Eugene
McDougle, Christopher J.
MetadataShow full item record
Publisher:American Psychiatric Publishing
Citation:Andrés Martin et al, "Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data," The American Journal of Psychiatry 161, no. 6 (2004)
Objective: The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change. Method: Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months. Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site, gender, age, and risperidone dose. Results: Age- and gender-standardized weight increased after 6 months of treatment (gross: mean=5.6 kg [SD=3.9]; standardized: mean=0.6 z [SD=0.5]) and was positively correlated with weight gained after 1 month. Change in leptin levels after 2 months of treatment (mean= –0.3 ng/ml, SD=6.2)(N=48) did not predict final weight gain. Conclusions: Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time. Serum leptin change does not reliably predict risperidone-associated weight gain.